Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Duration: September 15, 2006
to
December 31, 2019
General Issues: Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Health Issues , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark , Financial Institutions/Investments/Securities
Spending: about $2,430,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2006: U.S. Senate, House of Representatives, U.S. Senate,, Y
Y
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Charles Brain Asst. to the President, Dp.Chief Staff W&M Cmte
Asst to the President, Dpty COS W&M Comm
Asst. to the President, Dp.Chief Staff W&M Cmte.
NA
Special Assistant to the President; Deputy COS Ways and Means Committee
A.J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
Senior Leg Asst, Cong Earl Pomeroy
Senior Legislative Asst. Cong .Earl Pomeroy
NA
Senior Legislative Aide, Rep. Earl Pomeroy
Beau Schuyler LD-CongTanner,LD-CongMcIntyre,SA-CongRose
LD-CongTanner,LD-Cong.McIntyre,SA-CongRose
LD - Rep. John Tanner, LD - Rep. Mike McIntyre, SA - Rep. Rose
LD-Cong. John Tanner, LD-Cong. Mike McIntyre
LD-CongTanner,LD-CongMcIntyre,LD-CongRose
Heather McHugh Legislative Director, Sen. Chuck Schumer
Leg. Dir. Sen. Chuck Schumer
Legislative Direector, Sen. Chuck Schumer
A. J. Wojciak Senior Legislative Asst., Cong. Earl Pomeroy
NA
Paul Bock Chief of Staff, Sen. Kohl
Charles Brain Mr. n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2019
Capitol Hill Strategies, LLC terminated an engagement in which they represented BIOTECHNOLOGY INDUSTRY ORGANIZATION on Jan. 16, 2020.
Original Filing: 301107214.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 10, 2019.
Original Filing: 301064438.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 15, 2019.
Original Filing: 301045745.xml
Lobbying Issues
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals.
Issues relating to biologics and biosimilars in Medicare and generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax provisions covering the pharmaceutical and biologic industries.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues relating to trade agreements regarding pharmaceutical and biologic patents and intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 15, 2019.
Original Filing: 301025260.xml
Lobbying Issues
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The American Innovation Act, proposed legislation on the preservation of start-up NOLS and tax credits.
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers,
S. 617, Tax Extender and Disaster Relief Act of 2019, legislation to amend the Internal Revenue Code of 1986 to extend certain expiring provisions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight.
H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity.
H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book
H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing
S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights.
Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines.
H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
Capitol Hill Strategies, LLC amended a lobbying report for representation of BIOTECHNOLOGY INDUSTRY ORGANIZATION in Q12019 on April 15, 2019.
Original Filing: 301025267.xml
Lobbying Issues
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Agencies Lobbied
U.S. Senate
Lobbying Issues
The American Innovation Act, proposed legislation on the preservation of start-up NOLS and tax credits.
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers,
S. 617, Tax Extender and Disaster Relief Act of 2019, legislation to amend the Internal Revenue Code of 1986 to extend certain expiring provisions
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight.
H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity.
H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book
H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing
S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights.
Vaccine Access Improvement Act, proposed legislation relating to the excise tax on specified vaccines.
H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 15, 2019.
Original Filing: 301004644.xml
Lobbying Issues
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
H.R. 6, Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988897.xml
Lobbying Issues
H.R. 1892, Bipartisan Budget Act of 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
H.R. 6, Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 19, 2018.
Original Filing: 300969733.xml
Lobbying Issues
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
H.R. 6Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 13, 2018.
Original Filing: 300944493.xml
Lobbying Issues
H.R. 1625, Consolidated Appropriations Act, 2018, provisions relating to manufacturers share of cost-sharing for Medicare beneficiaries in the donut hole phase of Part D plan coverage.
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
Legislation to address opioids manufacturing and distribution
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA), vaccines and other various provisions.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 16, 2018.
Original Filing: 300924389.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
H.R. 4710, 340B PAUSE Act, establishing a moratorium on the registration of new 340B hospitals and associated sites, and requiring reporting of program data.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
H.R. 1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018; specifically, changes to the orphan drug tax credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 17, 2017.
Original Filing: 300905149.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
H.R. 3921, Healthy Kids Act, a bill to extend funding for the Childrens Health Insurance Program, and for other purposes; potential provisions offsetting the cost of the bill and amendments relating to Secretarial non-interference.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 18, 2017.
Original Filing: 300886987.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300872581.xml
Lobbying Issues
H.R. 849, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
S. 251, Protecting Seniors' Access to Medicare Act of 2017, a bill to repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board (IPAB).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Legislation to provide renewable chemical producers access to production tax credits currently available for other renewable energy producers.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
PDUFA Reauthorization legislation (bill text and number pending), legislation to reauthorize the Prescription Drug User Fee Act (PDUFA), as reauthorized by the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 1628, American Health Care Act of 2017, reconciliation legislation repealing significant portions of the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848288.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Debt-Equity Regulations issued under IRC Section 385.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 34, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2016
In Q3, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 19, 2016.
Original Filing: 300831614.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Debt-Equity Regulations issued under IRC Section 385.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 19, 2016.
Original Filing: 300814784.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures.
Debt-Equity Regulations issued under IRC Section 385.
H.R. 4139, The Fostering Innovation Act
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300798066.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
CMS proposed rule potential and potential legislation that includes provisions that would alter payment policies under Medicare Part B for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to amend the Internal Revenue Code of 1986 regarding the Orphan Drug Tax Credit.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 18, 2016.
Original Filing: 300774266.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
Potential Medicare legislation that includes revenue raising provisions that would reduce Medicare Part B reimbursements for drugs and biologics
H.R. 1190 - Protecting Seniors Access to Medicare Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to amend the Internal Revenue Code of 1986 regarding the Orphan Drug Tax Credit.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300765129.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
Potential Medicare legislation that includes revenue raising provisions that would reduce Medicare Part B reimbursements for drugs and biologics
H.R. 1190 - Protecting Seniors Access to Medicare Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to amend the Internal Revenue Code of 1986 regarding the Orphan Drug Tax Credit.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Senate Innovations for Healthy Americans Act (text not yet available but likely multiple provisions similar to H.R. 6 including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 15, 2015.
Original Filing: 300734900.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (potential revenue raising and cost saving provisions)
Potential Medicare legislation that includes revenue raising provisions that would reduce Medicare Part B reimbursements for drugs and biologics
H.R. 1190 - Protecting Seniors Access to Medicare Act of 2015
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 9, Innovation Act (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
S. 1137, Protecting American Talent and Entrepreneurship Act of 2015 (Inter partes review provisions and other provisions relating to patents covered by Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA)).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
H.R. 2179. Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research Act (PARTNER Act)
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain pre-revenue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to amend the Internal Revenue Code of 1986 regarding the Orphan Drug Tax Credit.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)
S. 320, The Medical Innovation Act. Legislation to authorize the collection of supplemental payments to increase congressional investments in medical research.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, Capitol Hill Strategies, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 15, 2015.
Original Filing: 300716121.xml
Lobbying Issues
Potential legislation or legislative provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs)
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015 (potential revenue raising and cost saving provisions)
H. Con. Res. 27, Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
S. Con. Res. 11, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025 (potential provisions relating to Medicare Part D and the establishment of a Medicaid style rebate, NIH funding provisions drawing funds from BIO/PhRMA industry government settlements, or other Medicare revenue raising provisions)
Potential Medicare legislation that includes revenue raising provisions that would reduce Medicare Part B reimbursements for drugs and biologics
Agencies Lobbied
U.S. Senate
Lobbying Issues
Draft 21st Century Cures legislation under consideration by the House Energy & Commerce Committee (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Patent Reform Legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 341, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment certain prerevnue companies including the treatment of net operating losses of high technology research small businesses corporations, Section 1202 Capital Gains Reform, and Section 469 R&D Partnership Structures,
Legislation to amend the Internal Revenue Code of 1986 regarding the Orphan Drug Tax Credit.
Comprehensive Tax Reform Legislation, generally
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 15, 2015.
Original Filing: 300696750.xml
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential programmatic offsets).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential programmatic offsets).
H.R. 83, Consolidated and Further Continuing Appropriations Act, 2015 (potential programmatic offsets)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4855, Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research (PARTNER) Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680257.xml
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4855, Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research (PARTNER) Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 18, 2014.
Original Filing: 300661064.xml
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309, Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4855, Partnerships to Advance Revolutionary Technology and Novel Entrepreneurial Research (PARTNER) Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on April 17, 2014.
Original Filing: 300639289.xml
Lobbying Issues
H. Con. Res. 96, Establishing the budget for the United States Government for fiscal year 2015 and setting forth appropriate budgetary levels for fiscal years 2016 through 2024, (potential provisions relating to Medicare Part D and the establishment of a Medicaid style "rebate").
S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act (potential revenue raising provisions).Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics.
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
H.R. 4302, Protecting Access to Medicare Act of 2014, (potential revenue raising provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Comprehensive Tax Reform Legislation, generally.
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309, Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2013
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616879.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013 (exempting industry funded user fees from sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare 340B program and proposed expansion thereof)
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations. S. 1658, Start-up Jobs and Innovation Act, legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309, Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2013
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596352.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)H.R. 3204, Drug Quality and Security Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013 (exempting industry funded user fees from sequester)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare 340B program and proposed expansion thereof)
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations. Legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $60,000. The report was filed on July 18, 2013.
Original Filing: 300576052.xml
Lobbying Issues
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions)
S.959, Pharmaceutical Compounding Quality and Accountability Act (state law pre-emption provisions, level of traceability provisions, upstream/downstream provisions, compounding oversight provisions)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare 340B program and proposed expansion thereof)
Potential deficit reduction legislation that might include provisions to reduce Medicare Part B reimbursements for drugs and biologics
H.R.1588, Medicare Drug Savings Act of 2013 (provisions relating to Medicare Part D and the establishment of a Medicaid style mandatory rebate on prescription drugs).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations. Legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.
H.R. 475, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).
S.391, A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on April 18, 2013.
Original Filing: 300553748.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. Con. Res. 25, Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023, (Provisions relating to Medicare 340B program and proposed expansion thereof)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation to amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
Legislation to amend the Internal Revenue Code of 1986 regarding the treatment of net operating losses of high technology research small businesses corporations. Legislation to amend the Internal Revenue Code of 1986 to modernize Section 1202 regarding the exclusion for gain from certain small business stock.
H.R. 475, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).
S.391, A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532948.xml
Lobbying Issues
Proposed legislation related to supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6621, To correct and improve certain provisions of the Leahy-Smith America Invents Act and title 35, United States Code.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 6559, To amend the Internal Revenue Code of 1986 to provide an exception from the passive loss rules for investments in high technology research small business pass-thru entities.
H.R.6687, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).S.3716, A bill to amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of taxable vaccines (quadravalent vaccines).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2012
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on Oct. 17, 2012.
Original Filing: 300509020.xml
Lobbying Issues
Proposed legislation related to Supply chain safety of pharmaceuticals and biologics, as considered in S. 3187 and related bills
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3606 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
S. 1933 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
2nd Quarter, 2012
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on July 17, 2012.
Original Filing: 300486345.xml
Lobbying Issues
H.R. 5651, Food and Drug Administration Reform Act of 2012 (provisions related to supply chain safety, exclusivity and incentives for pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement)S. 3187, Food and Drug Administration Safety and Innovation Act (provisions related to supply chain safety, pediatric drugs, drug shortages and the underlying PDUFA reauthorization agreement; potential amendments/provisions including patent settlements and importation)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3606 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
S. 1933 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
1st Quarter, 2012
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on April 18, 2012.
Original Filing: 300464497.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
HR 2405, Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Prescription Drug User Fee Act Reauthorization legislation underlying reauthorization for FDA approval process and other issues that are being considered for inclusion in the legislative package such as up and downstream supply chain safety, pediatric exclusivity and incentive provisions, track and trace provisions, and drug shortages provisions.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
FY 2013 Budget of the United States Government, issues related to the Therapeutic Discovery Project Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3606 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
S. 1933 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on Jan. 19, 2012.
Original Filing: 300444571.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
HR 2405, Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
H.R.2112 Consolidated and Further Continuing Appropriations Act, 2012 (S.AMDT.769, Sen. Vitter Amendment on pharmaceutical importation)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
FY 2012 Budget of the United States Government, issues related to the Therapeutic Discovery Project Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3606 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
S. 1933 Reopening American Capital Markets to Emerging Growth Companies Act of 2011.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
Lobbying Issues
Negotiations of the Joint Select Committee on Deficit Reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)S 27. Preserve Access to Affordable Generics Act
H.R.3630, Temporary Payroll Tax Cut Continuation Act of 2011 (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on Oct. 18, 2011.
Original Filing: 300417084.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
S 27. Preserve Access to Affordable Generics Act
HR 2405, Pandemic and All-Hazards Preparedness Reauthorization Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
FY 2012 Budget of the United States Government, issues related to the Therapeutic Discovery Project Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.23, America Invents Act
H.R. 1249, Leahy-Smith America Invents Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Bipartisan, bicameral negotiations on legislative framework for comprehensive deficit reduction (Medicare Part D provisions; Medicare Part B drug reimbursements)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $30,000. The report was filed on July 15, 2011.
Original Filing: 300391234.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
FY 2012 Budget of the United States Government, issues related to the Therapeutic Discovery Project Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.23, America Invents Act
H.R. 1249, Leahy-Smith America Invents Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Bipartisan, bicameral negotiations on legislative framework for comprehensive deficit reduction (Medicare Part D provisions)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $40,000. The report was filed on April 19, 2011.
Original Filing: 300371086.xml
Lobbying Issues
H.R. 452, To repeal the provisions of the Patient Protection and Affordable Care Act providing for the Independent Payment Advisory Board
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 942, the American Research and Competitiveness Act of 2011
FY 2012 Budget of the United States Government, issues related to the Therapeutic Discovery Project Credit
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.23, America Invents Act
H.R. 1249, America Invents Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $50,000. The report was filed on Jan. 17, 2011.
Original Filing: 300339251.xml
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act (membership and formation of comparative effectiveness research entity, the Patient-Centered Outcomes Research Institute (PCORI) created in this law)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.4853, Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010 (Therapeutic Discovery Project Credit)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2010
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $50,000. The report was filed on Oct. 12, 2010.
Original Filing: 300310968.xml
Lobbying Issues
H.R. 4213, Unemployment Compensation Extension Act of 2010 (340b provisions)
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions, BioShield funding, AMP provisions, patent settlement provisions)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $50,000. The report was filed on July 15, 2010.
Original Filing: 300287155.xml
Lobbying Issues
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010 (340b provisions)
H.R. 4899, the Supplemental Appropriations Act of 2010 (340b provisions, BioShield funding, AMP provisions, patent settlement provisions)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $40,000. The report was filed on April 17, 2010.
Original Filing: 300261555.xml
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Comparative Effectiveness Research, Follow on Biologics, Medicare 340B provisions, therapeutic tax credit provisions)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $40,000. The report was filed on Jan. 18, 2010.
Original Filing: 300234384.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act (Biosimilars)
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. 1679, the Affordable Health Choices Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3590, the Patient Protection and Affordable Care Act of 2009 (Comparative Effectiveness Research, Follow on Biologics)
H.R. 3962, America's Affordable Health Choices Act of 2009 (Comparative Effectiveness Research, Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $40,000. The report was filed on Oct. 16, 2009.
Original Filing: 300208499.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act (Biosimilars)
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. 1679, the Affordable Health Choices Act
H.R. 3200, America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. ____, Americas Healthy Future Act of 2009 (Comparative Effectiveness Research)
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $50,000. The report was filed on July 15, 2009.
Original Filing: 300178732.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act (Biosimilars)
H.R. 2502, Comparative Effectiveness Research Act of 2009
S. 1213, Patient-Centered Outcomes Research Act of 2009S. ____ [Draft of HELP Committee health care reform bill], Affordable Health Choices Act (Biologics Price Competition and Innovation provisions)
H.R. 3200, Americas Affordable Health Choices Act (Comparative Effectiveness Research)
S. ____, Senate Finance Committee Health Care Reform Options (Comparative Effectiveness Research)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ORGANIZATION , earning $50,000. The report was filed on April 17, 2009.
Original Filing: 300153667.xml
Lobbying Issues
H.R. 1548, Pathway for Biosimilars Act of 2009
H.R. 1427, Promoting Innovation and Access to Life-saving Medicines Act (Biosimilars)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1, American Recovery and Reinvestment Act of 2009 (Comparative Effectiveness Research Provisions)
H.R. 2, Children's Health Insurance Program Reauthorization Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 629, Energy and Commerce Recovery and Reinvestment Act (Medicare Part D provisions)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ASSOCIATION , earning $40,000. The report was filed on Jan. 14, 2009.
Original Filing: 300118378.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 (Follow on Biologics)
H.R. 5629, the Pathway for Biosimilars Act (Follow on Biologics)
H.R. 1038, Access to Life-Saving Medicine Act; (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
S. 3408, Comparative Effectiveness Research Act of 2008
H.R. 3162, CHAMP Act (Comparative Effectiveness provisions)
H.R. 2184, Enhanced Health Care Value for All Act of 2007 (Comparative Effectiveness provisions)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 1424, Emergency Economic Stabilization Act of 2008 (R&D Tax Credit; Paul Wellstone Mental Health and Addiction Equity title - Medicaid rebate)
H.R. 6983, Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (Medicaid Rebate)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ASSOCIATION , earning $40,000. The report was filed on Oct. 8, 2008.
Original Filing: 300089117.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007 (Follow on Biologics)
H.R. 5629, the Pathway for Biosimilars Act (Follow on Biologics)
H.R. 1038, Access to Life-Saving Medicine Act; (Follow on Biologics)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
S. 3408, Comparative Effectiveness Research Act of 2008
H.R. 3162, CHAMP Act (Comparative Effectiveness provisions)
H.R. 2184, Enhanced Health Care Value for All Act of 2007 (Comparative Effectiveness provisions)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 7060, Renewable Energy and Job Creation Tax Act of 2008 (R&D Tax Credit)
H.R. 7202, Temporary Tax Relief Act of 2008 (R&D Tax Credit)
H.R. 1424, Emergency Economic Stabilization Act of 2008 (R&D Tax Credit)
H.R. 6049, Energy Improvement and Extension Act of 2008 (R&D Tax Credit)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2008
In Q2, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ASSOCIATION , earning $40,000. The report was filed on July 16, 2008.
Original Filing: 300067251.xml
Lobbying Issues
H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007
H.R. 5629, Pathway for Biosimilars Act
H.R. 1038, Access to Life-Saving Medicine Act; (Follow on Biologics)
H.R. 5839, the Safeguarding Americas Pharmaceuticals Act, (Counterfeit medicines)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6381, Medical Device Safety Act of 2008 (Pre-emption legislation to overturn Riegel v. Medtronic)
H.R. 1424, Paul Wellstone Mental Health and Addiction Equity Act (Medicaid Rebate)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Food and Drug Administration Globalization Act of 2008, House Energy & Commerce discussion draft (Import Safety)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 3162, CHAMP Act; Baucus-Conrad bill (draft released, not introduced)
H.R. 2184, Enhanced Health Care Value for All Act of 2007; (Comparative Effectiveness provisions of each)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H.R. 6049, The Renewable Energy and Job Creation Act. (R& D Extension)
H.R. 3221, The American Housing Rescue and Foreclosure Prevention Act of 2008. (R&D/AMT Credits)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2008
In Q1, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ASSOCIATION , earning $40,000. The report was filed on April 18, 2008.
Original Filing: 300044677.xml
Lobbying Issues
Follow on Biologic legislation:
H.R. 1038 Access to Life-saving Medicines Act
H.R. 1956 Patient Protection and Innovative Biologics Medicines Act of 2007
H.R. 5629 Pathway for Biosimilars Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid Rebate: Mental Health Parity bill (H.R. 1424)
Comparative Effectiveness: Champ Act (H.R. 3162); Baucus -Conrad bill (proposed,not yet introduced); Allen bill (H.R. 2184)
Agencies Lobbied
U.S. House of Representatives
0th Quarter, 2007
In MM, CAPITOL HILL STRATEGIES, LLC lobbied for BIOTECHNOLOGY INDUSTRY ASSOCIATION , earning $60,000. The report was filed on July 29, 2007.
Original Filing: 200042216.xml
Lobbying Issues
Medicare Part D Reimbursement
Lobbying Issues
Patent Reform; Follow On Biologics
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2006
Capitol Hill Strategies, LLC filed a lobbying registration on Oct. 19, 2006 to represent Biotechnology Industry Association, effective Sept. 15, 2006.
Original Filing: 100051390.xml
Issue(s) they said they’d lobby about: Medicare, Patent Reform, Medicaid .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...